Showing results (291-300 of 461) with videos related to

Sort By:
Pageof 47
Leukemia|December 16, 2024
Capillary leak phenotype as a major cause of death in patients with POEMS syndromeKenzie Lee, Taxiarchis Kourelis, Marcella Tschautscher, et al.
Haematologica|May 22, 2025
Clonal plasma cell features in light-chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic responseMatthew J Rees, Susan Geyer, Binoy Yohannan, et al.
Blood Advances|June 25, 2026
Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System InvolvementAlexander Xiao, Saurabh S Zanwar, Yi Lin, et al.
Blood|October 13, 2016
The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatmentEli Muchtar, Dragan Jevremovic, Angela Dispenzieri, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 28, 2012
Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilizationIvana N M Micallef, Shirshendu Sinha, Dennis A Gastineau, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 16, 2018
Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple MyelomaAnkit Kansagra, Wilson I Gonsalves, Morie A Gertz, et al.
Leukemia|September 28, 2025
Refining PET-based response in extramedullary multiple myeloma using total lesion glycolysisSaurabh Zanwar, Gokce Belge Bilgin, Stephen M Broski, et al.
Bone Marrow Transplantation|June 22, 2026
Autologous stem cell transplantation for AL amyloidosis: a multicenter summary of outcomes 2010-2020Ben Lerman, Stefan Schönland, Ute Hegenbart, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 4, 2020
Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma PatientsAbdullah S Al Saleh, Harsh V Parmar, Alissa Visram, et al.
British Journal of Haematology|November 24, 2011
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myelomaMeaghan L Khan, Craig B Reeder, Shaji K Kumar, et al.
Pageof 47